Clinical Trial

A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease

Study acronym: MINDSET 1
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC for cognitive impairment in Alzheimer's Disease
Protocol Amendment History 2 changes
notable Trial sites expanded: 106 -> 116 locations 2026-06-27
notable Trial sites reduced: 109 -> 106 locations 2026-04-15
Trial Details
NCT Number NCT06976216
Lead Sponsor Bristol-Myers Squibb
Conditions Alzheimer's Disease
Enrollment 586 participants
Start Date 2025-07-14
Primary Completion 2028-09-11 (estimated)
Study Completion 2029-02-23 (estimated)
Updated on ClinicalTrials.gov 2026-06-26